Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Clinical trial NCT03532217 · COMPLETED
Trial details
- NCT number
- NCT03532217
- Sponsor
- Washington University School of Medicine
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-14
- Primary completion
- 2022-04-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.